Drug Profile
D 6428
Latest Information Update: 23 Jan 2004
Price :
$50
*
At a glance
- Originator Celltech Group; Penwest Pharmaceuticals
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 23 Jan 2004 Discontinued - Phase-I for Pain in United Kingdom (PO)
- 23 Jan 2004 Discontinued - Phase-I for Pain in USA (PO)
- 15 Dec 2000 Phase-I clinical trials for Pain in United Kingdom (PO)